Several other analysts also recently weighed in on the company. Vetr raised Illumina from a buy rating to a strong-buy rating and set a $148.34 target price for the company in a report on Tuesday, January 3rd. Zacks Investment Research raised Illumina from a sell rating to a hold rating in a report on Tuesday, December 13th. Morgan Stanley reduced their target price on Illumina from $115.00 to $100.00 and set an underweight rating for the company in a report on Wednesday, December 7th. TheStreet downgraded Illumina from a buy rating to a hold rating in a report on Monday, December 5th. Finally, Leerink Swann assumed coverage on Illumina in a report on Thursday, November 10th. They issued a market perform rating and a $145.00 target price for the company. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $152.67.
Illumina (NASDAQ:ILMN) traded down 1.00% during trading on Friday, hitting $163.39. The stock had a trading volume of 1,294,292 shares. The firm has a market cap of $24.00 billion, a P/E ratio of 54.83 and a beta of 1.16. The stock’s 50 day moving average price is $130.13 and its 200 day moving average price is $150.44. Illumina has a 12-month low of $119.37 and a 12-month high of $186.88.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The business earned $607 million during the quarter, compared to the consensus estimate of $628.06 million. During the same period in the previous year, the business earned $0.80 EPS. The business’s quarterly revenue was up 10.4% on a year-over-year basis. On average, analysts anticipate that Illumina will post $3.32 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2017/01/11/illumina-inc-ilmn-raised-to-buy-at-cl-king.html.
In related news, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $135.01, for a total value of $81,006.00. Following the sale, the director now owns 17,065 shares of the company’s stock, valued at approximately $2,303,945.65. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Omead Ostadan sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $126.16, for a total value of $252,320.00. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of ILMN. ProVise Management Group LLC raised its stake in Illumina by 11.2% in the second quarter. ProVise Management Group LLC now owns 2,292 shares of the life sciences company’s stock worth $322,000 after buying an additional 230 shares during the last quarter. Douglas Lane & Associates LLC raised its stake in Illumina by 3.2% in the second quarter. Douglas Lane & Associates LLC now owns 441,993 shares of the life sciences company’s stock worth $62,047,000 after buying an additional 13,639 shares during the last quarter. Prudential Financial Inc. raised its stake in Illumina by 0.3% in the third quarter. Prudential Financial Inc. now owns 202,670 shares of the life sciences company’s stock worth $36,817,000 after buying an additional 655 shares during the last quarter. Gulf International Bank UK Ltd raised its stake in Illumina by 0.8% in the third quarter. Gulf International Bank UK Ltd now owns 44,340 shares of the life sciences company’s stock worth $8,054,000 after buying an additional 350 shares during the last quarter. Finally, Westpac Banking Corp bought a new stake in Illumina during the third quarter worth about $4,870,000. 92.94% of the stock is currently owned by hedge funds and other institutional investors.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.